Loxo Oncology, Inc., a development-stage company, develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase, which is in a Phase I dose escalation trial for the treatment of patients with advanced solid tumor types, such as neuroblastoma and lung, thyroid, and breast cancers. The company is also developing a pipeline of additional product candidates targeting cancers driven by genetic alterations. Loxo Oncology, Inc. has a drug discovery collaboration agreement with Array BioPharma Inc. The company was founded in 2013 and is ...
One Landmark Square
Stamford, CT 06901
Founded in 2013
Loxo Oncology, Inc. Announces Management Appointments
May 6 14
Loxo Oncology, Inc. announced the appointment of Mikel Moyer, PhD, as chief scientific officer. Dr. Moyer was most recently the vice president of molecular discovery at Epizyme. Dr. Barrett will join Loxo Oncology's board of directors. Sara Nayeem, MD, a principal at NEA, will also join the board as an observer.
Loxo Oncology Initiates Phase 1 Trial of LOXO 101, a Selective TRK Inhibitor
May 1 14
Loxo Oncology, Inc. announced that it has initiated a Phase 1 Study for its lead compound, LOXO-101, a potent and selective inhibitor of the tropomyosin kinase (TRK) family of receptors. The Phase 1 study will evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of LOXO-101 and, in a second stage, will also provide a preliminary assessment of anti-tumor activity in cancer patients preselected to have an alteration in genes affecting the TRKA, TRKB or TRKC proteins. The advancement of LOXO-101 into the clinic is an important milestone for it. It exemplifies its approach to targeted drug development - the application of compelling chemistry to a promising target in a genetically-defined patient population. Loxo Oncology retains all development and commercialization rights to its TRK inhibitor program, which includes LOXO-101.
Loxo Oncology, Inc. Announces Board Appointments
Oct 3 13
Loxo Oncology, Inc. announced that it has completed a $33 million Series A financing round. The round included founding investor Aisling Capital and new investors OrbiMed Advisors LLC and an undisclosed investor. In conjunction with the financing, the company announced Keith Flaherty, M.D., director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital to its Board of Directors. Additionally, Loxo Oncology appointed four new members to its Scientific Advisory Board. These nationally-recognized physician/scientists are providing critical advice and expertise to the company around rational target selection, product profile definition and clinical development strategy. In addition to Dr. Flaherty, who is chair of the Scientific Advisory Board, the new members include: Jeffrey A. Engelman, M.D., Ph.D., director, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center; associate professor of Medicine, Harvard Medical School. Ross L. Levine, M.D., associate member, Human Oncology and Pathogenesis Program, and associate attending physician, Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; associate professor of Medicine, Weill Cornell Medical College. Ben Ho Park, M.D., Ph.D., associate professor of Oncology, Breast Cancer Research Program, and Joint Appointment, Whiting School of Engineering, Department of Chemical and Biomolecular Engineering, Johns Hopkins University; attending physician, Johns Hopkins Hospital, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. David Solit, M.D., Ph.D., director, Developmental Therapeutics, and associate professor of Medicine, Cell and Developmental Biology, Memorial Sloan-Kettering Cancer Center.